|
1
|
Berger J and Hinglais N: Intercapillary
deposits of IgA-IgG. J Urol Nephrol (Paris). 74:694–695. 1968.(In
French). PubMed/NCBI
|
|
2
|
Bartosik LP, Lajoie G, Sugar L and Cattran
DC: Predicting progression in IgA nephropathy. Am J Kidney Dis.
38:728–735. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
D Amico G: Natural history of idiopathic
IgA nephropathy: Role of clinical and histological prognostic
factors. Am J Kidney Dis. 36:227–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alamartine E, Sabatier JC, Guerin C,
Berliet JM and Berthoux F: Prognostic factors in mesangial IgA
glomerulonephritis: An extensive study with univariate and
multivariate analyses. Am J Kidney Dis. 18:12–19. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bogenschütz O, Bohle A, Batz C, Wehrmann
M, Pressler H, Kendziorra H and Gärtner HV: IgA nephritis: On the
importance of morphological and clinical parameters in the
long-term prognosis of 239 patients. Am J Nephrol. 10:137–147.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reich HN, Troyanov S, Scholey JW and
Cattran DC: Toronto Glomerulonephritis Registry: Remission of
proteinuria improves prognosis in IgA nephropathy. J Am Soc
Nephrol. 18:3177–3183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beck L, Bomback AS, Choi MJ, Holzman LB,
Langford C, Mariani LH, Somers MJ, Trachtman H and Waldman M: KDOQI
US commentary on the 2012 KDIGO clinical practice guideline for
glomerulonephritis. Am J Kidney Dis. 62:403–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jadad AR, Moore RA, Carroll D, Jenkinson
C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang S: Clinical observation of
Benazepril combined with azathioprine on IgA nephropathy. Guo Ji Yi
Yao Wei Sheng. 20:53–55. 2009.
|
|
10
|
Kuang B: Clinical observation of
Benazepril combined with azathioprine on IgA nephropathy. ZhongGuo
Xian Dai Yi Sheng. 19:6–7. 2010.
|
|
11
|
Li YN: Curative effect analysis of
Benazepril combined with azathioprine on IgA nephropathy along with
the amount of proteinuria. Hua Bei Mei Tan Yi Xue Yuan XueBao.
4:471–472. 2011.
|
|
12
|
Ma FL: Clinical research oil azathioprine
combined with benazepril treating IgA nephropathy. Xian Dai Zhen
Duan Yu Zhi Liao. 6:653–654. 2012.
|
|
13
|
Xu H: Azathioprine and prednisone,
valsartan Clinical observation on treatment of IgA nephropathy. Zhe
Jiang Yi Xue. 3:227–229. 2013.
|
|
14
|
Chen XM, Chen P, Cai G, Wu J, Cui Y, Zhang
Y, Liu S and Tang L: A randomized control trial of mycophenolate
mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi.
82:796–801. 2002.(In Chinese). PubMed/NCBI
|
|
15
|
Chen XSh: Clinic Effect of Mycophenolate
Mofetil combined Valsartan on IgA Nephropathy. Zhong Guo Yi Yao Zhi
Nan. 20:53–54. 2010.
|
|
16
|
Guo QY: Efficacy of pediatric IgA
nephropathy mycophenolate mofetil combined hormone therapy. Guang
Dong Yi Xue. 7:902–903. 2010.
|
|
17
|
Huang Zh: Efficacy of focal proliferative
sclerosing 38 cases of patients with IgA nephropathy. He Nan Yi Xue
Yan Jiu. 4:437–439. 2012.
|
|
18
|
Tang SC, Tang AW, Wong SS, Leung JC, Ho YW
and Lai KN: Long-term study of mycophenolate mofetil treatment in
IgA nephropathy. Kidney Int. 77:543–549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang WM: Clinical study on treatment of
IgA nephropathy with renal insufficiency by corticosteroid,
corticosteroid combined with cyclophosphamide and corticosteroid
combined with mycophenolate mofetil. Shang Hai Jiao Tong Da Xue Xue
Bao. 2:162–167, 173. 2013.
|
|
20
|
Cao LO: Leflunomide in combination with
medium/low dose of prednisolone in treatment of progressive IgA
nephropathy. Shanghai Yi Xue. 9:791–795. 2009.
|
|
21
|
Fu Q: Effects of leflunomide combined with
hormone therapy for lg a nephropathy. Shan Xi Yi Xue Za Zhi.
3:351–353. 2009.
|
|
22
|
Hu RH: IgA nephropathy leflunomide
combined with hormone therapy. J Clinical Internal Medicine.
12:837–839. 2011.
|
|
23
|
Huang YX: Leflunomide combined small dose
glucocorticoid treatment of progressive IgA nephropathy Efficacy.
Chinese Journal of Primary Medicine and Pharmacy. 18:1965–1966.
2011.
|
|
24
|
Li T: Study on effect of leflunomide
combined with glucocorticoid in treatment of progressive IgA
nephropathy. Modern J Integrated Traditional Chinese and Western
Medicine. 1:13–15. 2011.
|
|
25
|
Lou TQ: Controlled trial of leflunomide in
the treatment of immunoglobulin a nephropathy. Journal of Sun
Yat-sem University (Medical Sciences). 5:570–572. 2005.
|
|
26
|
Pu L: Efficacy of benazepril combined with
leflunomide in treatment of IgA nephropathy. Jiangsu Medical
Journal. 11:1277–1279. 2012.
|
|
27
|
Shen P: Leflunomide combined with low-dose
hormone therapy efficacy of IgA nephropathy. Chinese J General
Practice. 10:1580–1581. 2012.
|
|
28
|
Sun MD: Clinical observation of
leflunomide treatment of IgA nephropathy. Chinese J Gerontology.
16:2038–2039. 2009.
|
|
29
|
Wang L: Leflunomide combined with
prednisone treatment of progressive IgA nephropathy Chronic. Suzhou
University J Medical Science. 4:677–679. 2006.
|
|
30
|
Yang FY: Controlled studies of leflunomide
treatment of IgA nephropathy. China Practical Medical. 22:17–19.
2009.
|
|
31
|
Zhang LW: Efficacy of leflunomide combined
with hormone treatment of chronic progressive IgA nephropathy.
Chinese Journal of Modern Drug Application. 20:116–118. 2010.
|
|
32
|
Zhang Y: Efficacy of leflunomide combined
with prednisone in the treatment of advanced IgA nephropathy.
Academic J Guangzhou Medical College. 23:82–85. 2010.
|
|
33
|
Liu Y: Accompanied by moderate proteinuria
treatment of IgA nephropathy. China Medical Herald. 6:23–24.
2006.
|
|
34
|
Guo M: Compare leflunomide or
cyclophosphamide combined hormone therapy of chronic progressive
IgA nephropathy. Guide of China Medicine. 28:142–143. 2012.
|
|
35
|
Sun ZhX: Comparison of the efficacy of
treatment with leflunomide and cyclophosphamide IgA nephropathy
renal dysfunction. Suzhou University J Medical Science. 5:961–963.
2009.
|
|
36
|
Zhang HF: Leflunomide combined with
glucocorticoids contrast cyclophosphamide glucocorticoid treatment
efficacy of IgA nephropathy. J Taishan Medical College. 6:434–436.
2013.
|
|
37
|
Zhong ShH: Controlled studies of
leflunomide and cyclophosphamide-based therapy to nephrotic
syndrome of IgA nephropathy. J North China Coal Medical University.
5:593–594. 2011.
|
|
38
|
Lv J, Xu D, Perkovic V, Ma X, Johnson DW,
Woodward M, Levin A, Zhang H and Wang H; TESTING Study Group, :
Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol.
23:1108–1116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Katafuchi R, Ninomiya T, Mizumasa T, Ikeda
K, Kumagai H, Nagata M and Hirakata H: The improvement of renal
survival with steroid pulse therapy in IgA nephropathy. Nephrol
Dial Transplant. 23:3915–3920. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoshikawa N, Honda M, Iijima K, Awazu M,
Hattori S, Nakanishi K and Ito H; Japanese Pediatric IgA
Nephropathy Treatment Study Group, : Steroid treatment for severe
childhood IgA nephropathy: A randomized, controlled trial. Clin J
Am Soc Nephrol. 1:511–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maes BD, Oyen R, Claes K, Evenepoel P,
Kuypers D, Vanwalleghem J, Van Damme B and Vanrenterghem YF:
Mycophenolate mofetil in IgA nephropathy: Results of a 3-year
prospective placebo-controlled randomized study. Kidney Int.
65:1842–1849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Frisch G, Lin J, Rosenstock J, Markowitz
G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A and
Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with
moderately advanced IgA nephropathy: A double-blind randomized
controlled trial. Nephrol Dial Transplant. 20:2139–2145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
